Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05327296 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)

A Phase 3 study of Sedation, sponsored by Sedana Medical.

Completed
Registry status
Phase 3
Development phase
282
Enrollment target
16
Study locations

NCT05327296: Completed Phase 3 study of Sedation, sponsored by Sedana Medical.

NCT05327296 is a Phase 3 study of Sedation that has completed, run by Sedana Medical. The registered enrollment target is 282 participants, below the 100,162-participant average among 12 other Sedation trials with a reported enrollment target (100% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05327296, a Phase 3 study of Sedation, has completed, sponsored by Sedana Medical.

COMPLETED
Registry status
Phase 3
Development phase
282 participants
Enrollment target
16
Study locations

Study Summary

This is a study to compare safety and efficacy of inhaled isoflurane administered via the Sedaconda ACD-S device system versus intravenous propofol for sedation of mechanically ventilated patients in the Intensive Care Unit (ICU) setting.

Primary Outcome

The Target Range is RASS -1 to -4. The Richmond Agitation-Sedation Scale (RASS) is used to measure the level of agitation or sedation in patients, particularly in critical care settings. It is a 10-point scale ranging from -5 to +4: +4 Combative - Violent, immediate danger to staff. +3 Very agitated - Pulls or removes tubes or catheters; aggressive. +2 Agitated - Frequent non-purposeful movement, fights ventilator. +1 Restless - Anxious but movements are not aggressive. 0 Alert and calm. -1 Dr

Conditions Studied

Interventions

  • DRUG Propofol
  • DRUG Isoflurane

Study Locations (16)

California

  • Memorial Health Services - Long Beach
  • University of California, Los Angeles - Los Angeles
  • Stanford University - Redwood City
  • University of California, San Diego - San Diego

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

Michigan

  • University of Michigan - Ann Arbor
  • Henry Ford Health System - Detroit

Florida

  • University of Miami - Coral Gables

Illinois

  • Rush University Medical Center - Chicago

New Jersey

  • The Cooper Health System - Camden

New York

  • The New York and Presbyterian Hospital - New York

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 282 participants
Start Date 2022-06-30
Est. Completion 2024-11-14
Phase Phase 3
Sedana Medical

3 total trials

What the finished NCT05327296 record still lists

NCT05327296 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, below the 100,162-participant average among 12 other Sedation trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Sedation appearing as the primary indexed condition, and to 2 interventions - of which Propofol is the first listed.

NCT05327296 lists 16 locations in 11 states (California, Massachusetts, Michigan).

Frequently Asked Questions

What is clinical trial NCT05327296 about?

NCT05327296 is a clinical study titled "Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)". This is a study to compare safety and efficacy of inhaled isoflurane administered via the Sedaconda ACD-S device system versus intravenous propofol for sedation of mechanically ventilated patients in the Intensive Care Unit (ICU) setting.

What is the current status of trial NCT05327296?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2022-06-30. Estimated completion is 2024-11-14.

What conditions does trial NCT05327296 study?

This clinical trial studies the following conditions: Sedation.

What interventions are being tested in trial NCT05327296?

The interventions under investigation include: Propofol (DRUG), Isoflurane (DRUG).

Who is sponsoring clinical trial NCT05327296?

This trial is sponsored by Sedana Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05327296 being conducted?

This trial has 16 study locations across California, Florida, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sedation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05327296's enrollment target sits among peer trials

282 4th of 12 higher than 9 of 12 other Sedation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sedation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02860364 · 282 participants · NA

    Comparing Hypothermic Temperatures During Hemiarch Surgery

  • NCT04867395 · 282 participants · NA

    A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity

  • NCT05101070 · 282 participants · Phase 1

    S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

  • NCT06276491 · 282 participants · Phase 1

    Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05327296, the US trial registry maintained by the National Library of Medicine. NCT05327296 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.